Linsitinib (OSI-906)

Catalog No.S1091

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Cited by 59 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 539(7630):570-574

PubMed: 27820945 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )
Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vN[2lEPTB;MD6wNlgxPiEQvF2=	M{\IR3NCVkeHUh?=
KS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjBSWdKSzVyPUCuNFM5OzVizszN	MmPVV2FPT0WU
TE-11	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEe4NlIh\|ryP	NGO0dYVUSU6JRWK=
EW-1	M3m4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH5TWM2OD1yLkC4OVg2KM7:TR?=	NGj3[plUSU6JRWK=
HMV-II	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYq5V3J{UUN3ME2wMlA5QDR4IN88US=>	NWrWZpRTW0GQR1XS
COLO-205	NIO0U3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zsTmlEPTB;MD6xNFQ2PCEQvF2=	MXvTRW5ITVJ?
ES1	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrHXmRKSzVyPUCuNVA3QTZizszN	NEDoW3RUSU6JRWK=
GDM-1	NFL4U2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMUO2O\|Ih\|ryP	M4HkW3NCVkeHUh?=
ML-2	M362TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMUW4PVYh\|ryP	NWLzflRGW0GQR1XS
Saos-2	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMU[1NlYh\|ryP	MVTTRW5ITVJ?
NCI-H1355	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMUixN\|Uh\|ryP	MWfTRW5ITVJ?
G-401	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXewToFsUUN3ME2wMlE5OjNizszN	M{n6c3NCVkeHUh?=
EW-16	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMUi3O\|ch\|ryP	NI\yTnRUSU6JRWK=
EW-7	M1r4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMUi4PFEh\|ryP	M373d3NCVkeHUh?=
NCI-H727	M4jSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVOxT2E{UUN3ME2wMlE6Pzl2IN88US=>	NYXWPJRtW0GQR1XS
LCLC-97TM1	M4nmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLzTWM2OD1yLkKwPVU2KM7:TR?=	MkHyV2FPT0WU
NCI-H650	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NES1VldKSzVyPUCuNlE{QDRizszN	NHfWd4RUSU6JRWK=
NCI-H2122	NGfkWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMkOyPVkh\|ryP	M3\MbnNCVkeHUh?=
SK-N-DZ	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMkO2PVgh\|ryP	MWLTRW5ITVJ?
HT-29	NVfrU3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV30[YM3UUN3ME2wMlI1OjR6IN88US=>	M1vNVnNCVkeHUh?=
LB771-HNC	NH3OTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL3U2F5UUN3ME2wMlI2QTF3IN88US=>	M3vqSXNCVkeHUh?=
HT-144	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnz4TWM2OD1yLkK2NVkyKM7:TR?=	MkHDV2FPT0WU
LAN-6	NHfrfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;4[WlEPTB;MD6yOlM1QCEQvF2=	M1vQOnNCVkeHUh?=
EW-18	M3XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHmR4ZFUUN3ME2wMlI4ODBzIN88US=>	Mki3V2FPT0WU
LS-1034	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PMeGlEPTB;MD6yO\|E{OiEQvF2=	MnfXV2FPT0WU
EW-11	NEXZXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTme\|JKSzVyPUCuNlg1OzJizszN	NV:y[YV6W0GQR1XS
SNU-C1	NWrMd255T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMkmzNVMh\|ryP	M4j5XHNCVkeHUh?=
RS4-11	NVnMWZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETOW3pKSzVyPUCuN\|M4PThizszN	M3Hoe3NCVkeHUh?=
ES4	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwNEGwN\|gh\|ryP	NH7sU3RUSU6JRWK=
COLO-320-HSR	NIrHZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwNEGzOlgh\|ryP	MnjhV2FPT0WU
NB10	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPFPVJKSzVyPUCuOFU1OzdizszN	M{PLcHNCVkeHUh?=
BFTC-905	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrNb4pSUUN3ME2wMlQ3PzV6IN88US=>	M{e1OXNCVkeHUh?=
A375	NIfUSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPLNGtKSzVyPUCuOFc3OTdizszN	NYO0cXNsW0GQR1XS
SJRH30	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;aRmlEPTB;MD61NFgzOiEQvF2=	NF\oc5lUSU6JRWK=
NOS-1	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrteFRKSzVyPUCuOVIzPjdizszN	NYG4SpFVW0GQR1XS
SIG-M5	NU[yRVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwNUO1OVch\|ryP	MXzTRW5ITVJ?
DOK	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\zTWM2OD1yLkW1OkDPxE1?	Mlf6V2FPT0WU
NB69	M3zQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3lVFFKSzVyPUCuOVgzPTdizszN	MojwV2FPT0WU
SK-NEP-1	M4jMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwNkCyN\|Yh\|ryP	M4PT[nNCVkeHUh?=
SK-MM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwNkW0PVEh\|ryP	M1HGbHNCVkeHUh?=
NCI-H358	NWjaXFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwNkewPFIh\|ryP	M4nEcHNCVkeHUh?=
RH-1	NWTacXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO3[VZKSzVyPUCuO\|Q5PTlizszN	Mlq0V2FPT0WU
NH-12	NFTuNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrWb4RjUUN3ME2wMlc3ODR4IN88US=>	MVLTRW5ITVJ?
TE-12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSyTWM2OD1yLke2OFg3KM7:TR?=	MnO5V2FPT0WU
COLO-668	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjteFFKSzVyPUCuPFQ3PjZizszN	M3jXeXNCVkeHUh?=
PANC-08-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwOE[zO\|ch\|ryP	NUPUfm83W0GQR1XS
HCC2998	NULWOYdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OxeGlEPTB;MD64PFI3OyEQvF2=	MWXTRW5ITVJ?
ABC-1	M2PrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn60TWM2OD1yLkmwN\|UzKM7:TR?=	NXW0N5J2W0GQR1XS
ES6	NHP3eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvFd2tOUUN3ME2wMlkyODZ4IN88US=>	MlXpV2FPT0WU
SNU-387	NGTZN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rxe2lEPTB;MD65PVM6OyEQvF2=	M1XFNHNCVkeHUh?=
CMK	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnS1TWM2OD1yLkm5PVI6KM7:TR?=	M173[3NCVkeHUh?=
SJSA-1	NUXZT4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTCTWM2OD1zLkCzOlU{KM7:TR?=	M{DmUHNCVkeHUh?=
SIMA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjBRmdKSzVyPUGuNFY5OjVizszN	NHy2U2VUSU6JRWK=
ES3	NH;SR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[5c5hqUUN3ME2xMlEzOjl5IN88US=>	NGDLXmNUSU6JRWK=
IGROV-1	NEXkdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUe3V4ZMUUN3ME2xMlE2PDR2IN88US=>	NXT4SotlW0GQR1XS
MEL-JUSO	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7FOIJyUUN3ME2xMlE2PzV7IN88US=>	M3[zOXNCVkeHUh?=
T84	M1v2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvOTWM2OD1zLkKwPVE1KM7:TR?=	M4\wUnNCVkeHUh?=
CAL-85-1	M3K0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFwMkOxN\|gh\|ryP	Mmj1V2FPT0WU
RD	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3znXGlEPTB;MT6yOlQ2PSEQvF2=	NWjTXnY2W0GQR1XS
TE-8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXHSWJKSzVyPUGuN\|E1PjJizszN	Moe2V2FPT0WU
L-363	M3i2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\2NXhKSzVyPUGuN\|QzODhizszN	M1fKTHNCVkeHUh?=
EKVX	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;neGpLUUN3ME2xMlM1PTZ6IN88US=>	M{mxfXNCVkeHUh?=
SK-MEL-3	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:4TWM2OD1zLkS4OVU3KM7:TR?=	NH;NXlRUSU6JRWK=
TGBC24TKB	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\UZWlEPTB;MT61NFE6OyEQvF2=	MWXTRW5ITVJ?
NCI-H1770	NVjIb2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HPNGlEPTB;MT61NVEyOyEQvF2=	MlL0V2FPT0WU
HuH-7	NET1OYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTpPGZoUUN3ME2xMlYxODl6IN88US=>	M1fzbnNCVkeHUh?=
HL-60	NFPTNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHu0[mtKSzVyPUGuOlY6OjhizszN	MX3TRW5ITVJ?
TE-1	NFnpbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwN{C5OFUh\|ryP	MY\TRW5ITVJ?
LC-2-ad	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwN{O4PFch\|ryP	MlLVV2FPT0WU
LB647-SCLC	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i0O2lEPTB;MT63OlU5OyEQvF2=	NF[yTZZUSU6JRWK=
NCI-H2171	NWjLeXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\MdJRnUUN3ME2xMlc4PzF4IN88US=>	MVvTRW5ITVJ?
SK-PN-DW	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEO0coJKSzVyPUGuPVEzQThizszN	M2HLe3NCVkeHUh?=
MC-IXC	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r3RmlEPTB;MT65PFk5KM7:TR?=	NV\hTVFrW0GQR1XS
LS-513	M3LmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTJwMEWzNFUh\|ryP	MmXGV2FPT0WU
EW-3	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorZTWM2OD1{LkC5PFQ1KM7:TR?=	MUPTRW5ITVJ?
OPM-2	M{fwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rIeWlEPTB;Mj6xNFIh\|ryP	MYPTRW5ITVJ?
LP-1	NWLHVnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[2eo5KSzVyPUKuNlU5ODdizszN	NFLXN2VUSU6JRWK=
LU-134-A	M13CbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTiW4lKSzVyPUKuNlc4KM7:TR?=	NWHpO\|hCW0GQR1XS
CP66-MEL	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fVOGlEPTB;Mj6yPVAyPCEQvF2=	MX;TRW5ITVJ?
HCC1143	M17nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLsTWM2OD1{LkS1N\|Y5KM7:TR?=	NVzUOWN3W0GQR1XS
LOXIMVI	NHz6TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HENmlEPTB;Mj62NFIyKM7:TR?=	NHnxVFdUSU6JRWK=
TE-10	NHfOTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjKbFZKSzVyPUKuO\|A5OzhizszN	NHLJdoRUSU6JRWK=
NCI-H1882	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJwN{WyNlch\|ryP	NXPnSHB4W0GQR1XS
CHP-126	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHv0fo9KSzVyPUKuO\|Y{OTdizszN	MVjTRW5ITVJ?
NCI-H1623	M3S0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;XWGlEPTB;Mj65NlAzPCEQvF2=	M{\Qd3NCVkeHUh?=
GB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTJwOUO0NFQh\|ryP	M{S3XnNCVkeHUh?=
RCC10RGB	NWTCSHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rpZWlEPTB;Mj65OVI5OSEQvF2=	NETGb2RUSU6JRWK=
NCI-H2141	NFPqXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfI[Y4{UUN3ME2yMlk3QDl4IN88US=>	MoToV2FPT0WU
GI-ME-N	M{[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPEclNKSzVyPUOuNFA2PjVizszN	NVny[nU2W0GQR1XS
NCI-H526	M1XUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3OTWM2OD1\|LkC0NFg2KM7:TR?=	NHrZc4xUSU6JRWK=
NCI-H747	NVTHNHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[xfHlsUUN3ME2zMlA1QTl{IN88US=>	M{Tqd3NCVkeHUh?=
SNU-423	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HlbWlEPTB;Mz6yNFMyOyEQvF2=	NHjVSnlUSU6JRWK=
A427	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GzWGlEPTB;Mz6yOVY6QSEQvF2=	MVXTRW5ITVJ?
CAL-12T	NVPR[2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\Bc2lEPTB;Mz60NFcyOyEQvF2=	MXLTRW5ITVJ?
LU-99A	NV;UVFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjCT49KSzVyPUOuOFcyODVizszN	M4rT[HNCVkeHUh?=
MS-1	NHTqU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfQT4pKSzVyPUOuOVM1OjlizszN	M33zfHNCVkeHUh?=
SK-LU-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XJOGlEPTB;Mz63OlI6PSEQvF2=	NWn0[49TW0GQR1XS
SW837	M1PWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfzTWM2OD1\|Lke2N\|M{KM7:TR?=	NGjzUVBUSU6JRWK=
ES8	NV73OYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfQTWM2OD1\|LkizPFc4KM7:TR?=	Ml7DV2FPT0WU
MZ2-MEL	M2jXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\0TWM2OD1\|LkmyNFg3KM7:TR?=	MVLTRW5ITVJ?
TGW	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWf6[XpvUUN3ME20MlAyOzFzIN88US=>	NV7aSlVbW0GQR1XS
GP5d	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m5V2lEPTB;ND6wOVM3OiEQvF2=	MmK1V2FPT0WU
BB49-HNC	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETTfINKSzVyPUSuNVUzOTNizszN	Mn7oV2FPT0WU
NB13	M2S2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7peHhWUUN3ME20MlI3QDh5IN88US=>	Ml\JV2FPT0WU
NTERA-S-cl-D1	NFHJdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXkUIFKSzVyPUSuNlg3OTVizszN	MYrTRW5ITVJ?
NCI-H1648	M3v1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTRwMkm4NVkh\|ryP	NHuwNmdUSU6JRWK=
LCLC-103H	NUXDTJpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPZTWM2OD12LkOyNVk2KM7:TR?=	MlfSV2FPT0WU
LS-411N	NVzaWnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfqR\|NKSzVyPUSuOFQ5QDVizszN	MoHqV2FPT0WU
NCI-H1092	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXLOVVKSzVyPUSuOFU3QDdizszN	NXfUfXJFW0GQR1XS
PANC-10-05	NXLwZog2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHlfWduUUN3ME20MlY6QDRizszN	NEDROXZUSU6JRWK=
DK-MG	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\hWY51UUN3ME20MlgxQTN\|IN88US=>	Ml7iV2FPT0WU
OVCAR-5	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPPTWM2OD12LkixNlI3KM7:TR?=	Mk\3V2FPT0WU
CAL-39	M1LuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTRwOEe2O{DPxE1?	NYLrNWtrW0GQR1XS
TE-441-T	M1rRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3JSpdsUUN3ME20MlkxPTN5IN88US=>	Ml;pV2FPT0WU
MOLT-16	NHm1Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HVSmlEPTB;ND65OVI2OyEQvF2=	MkHEV2FPT0WU
MCF7	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHpTWM2OD13LkG0OVE4KM7:TR?=	NYXo[oxZW0GQR1XS
CAPAN-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWL6cmtVUUN3ME21MlI2PzB5IN88US=>	M{Gzc3NCVkeHUh?=
PSN1	M3rER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3OzbGlEPTB;NT6yO\|I{PSEQvF2=	NEnoTnVUSU6JRWK=
NCI-H292	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLpTWM2OD13LkOwNFQ1KM7:TR?=	NH;NW4NUSU6JRWK=
CPC-N	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTVwM{m0NVkh\|ryP	MmjWV2FPT0WU
DoTc2-4510	NEXnZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XzTmlEPTB;NT60OVM4OSEQvF2=	MVTTRW5ITVJ?
LB1047-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\zTWM2OD13LkW1PVM{KM7:TR?=	MVrTRW5ITVJ?
MHH-ES-1	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTVwNUm5NFch\|ryP	MWPTRW5ITVJ?
NMC-G1	NUXJZXJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGD5RY1KSzVyPUWuO\|AzOjdizszN	NIPDN5NUSU6JRWK=
SW1710	NIrSdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTVwN{S3OVEh\|ryP	M2HyNnNCVkeHUh?=
YAPC	M174[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvJS3hKSzVyPUWuO\|YzODFizszN	MojZV2FPT0WU
22RV1	M{P0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HFfmlEPTB;NT64NFAyQSEQvF2=	M1foXnNCVkeHUh?=
COLO-679	M4XJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknxTWM2OD13Lki4PVQ5KM7:TR?=	M4e2WnNCVkeHUh?=
TCCSUP	NVfpZXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonrTWM2OD13LkmzNlU6KM7:TR?=	M4[0TXNCVkeHUh?=
C2BBe1	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTVwOUO5O{DPxE1?	MUXTRW5ITVJ?
TE-15	Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHiyU5FKSzVyPU[uNFY3ODVizszN	MomwV2FPT0WU
SCLC-21H	NXrxOnBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe0b4FKSzVyPU[uNVA5PDNizszN	NVv3XW5{W0GQR1XS
EoL-1-cell	M4nGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLUUHNOUUN3ME22MlE3PTZ\|IN88US=>	NVnHfllYW0GQR1XS
NKM-1	M16wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPLWGRKSzVyPU[uNVY4OSEQvF2=	NIn4SlFUSU6JRWK=
NCI-H1304	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTZwMke0Nlgh\|ryP	NXLxNWpTW0GQR1XS
NB6	NIDGNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTTVlBxUUN3ME22MlI6PjJ{IN88US=>	MU\TRW5ITVJ?
NALM-6	NYq4UJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnXVWFKSzVyPU[uN\|MzOyEQvF2=	NXfLeox4W0GQR1XS
NCI-H522	NU\rdpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LGN2lEPTB;Nj6zN\|MxPiEQvF2=	MV7TRW5ITVJ?
MV-4-11	NWq1NWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7pTWM2OD14LkO3NFc6KM7:TR?=	NYW2bmhQW0GQR1XS
LB2241-RCC	M2O1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoriTWM2OD14LkO4OlY4KM7:TR?=	M1rw[nNCVkeHUh?=
NCI-H1417	NYjVcYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\aTWM2OD14LkSwPFQ4KM7:TR?=	MnjZV2FPT0WU
HT-1197	NGXmVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnywTWM2OD14LkW3NVIzKM7:TR?=	NV\rU4VyW0GQR1XS
P30-OHK	NGHXZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLXTWM2OD14Lk[yO\|ch\|ryP	MkD1V2FPT0WU
ALL-PO	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PaOGlEPTB;Nj63NVkyPiEQvF2=	NXHw[\|hLW0GQR1XS
OVCAR-4	NEK0OpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTaeoJKSzVyPU[uO\|U1ODVizszN	M37ZbXNCVkeHUh?=
HCC2157	NEXK[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCwTXdFUUN3ME22Mlc4PDd3IN88US=>	M2XoTHNCVkeHUh?=
NCI-H838	NXP5dZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTZwOU[0PUDPxE1?	M1Pzc3NCVkeHUh?=
NCI-H1299	NYPaSZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvyTWM2OD14Lkm3NFkh\|ryP	NFzCTJFUSU6JRWK=
SW954	M33UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf5Z\|VsUUN3ME23MlIxODZ6IN88US=>	M2rUPXNCVkeHUh?=
NCI-H441	NEDnZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTdwM{SwOlUh\|ryP	MlTIV2FPT0WU
SK-MEL-2	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDlfZZKSzVyPUeuOFg{PzNizszN	M{fyfXNCVkeHUh?=
KARPAS-45	NIPxbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXGTWM2OD15Lk[1PVI6KM7:TR?=	MmTEV2FPT0WU
CAL-54	M13CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\JcFNSUUN3ME23MlgzQTd5IN88US=>	NHH0bpBUSU6JRWK=
KYSE-180	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYP6fY1{UUN3ME23Mlg5QTRzIN88US=>	Ml73V2FPT0WU
NCI-H187	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\2[GlEPTB;Nz65OVk1PyEQvF2=	NXTNdYpQW0GQR1XS
RT-112	M3TpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRThwMEm2O\|ch\|ryP	MnvXV2FPT0WU
NCI-H1437	NXzaRYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRThwMEm3PVUh\|ryP	MXzTRW5ITVJ?
SNU-449	M3TIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRThwMkiyO\|Ih\|ryP	M1i0bnNCVkeHUh?=
HCC1187	NFrNS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnsUFRKSzVyPUiuNlk{QTFizszN	MVfTRW5ITVJ?
NCI-H2030	NGrwVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRThwM{e3NVQh\|ryP	MYHTRW5ITVJ?
HuO-3N1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLaTWM2OD16LkO3PFQ1KM7:TR?=	NXfVSZlKW0GQR1XS
COLO-792	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILyeGFKSzVyPUiuOFE2OjdizszN	MnLOV2FPT0WU
MIA-PaCa-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRThwOEW1NFgh\|ryP	NWr5PXBtW0GQR1XS
SK-N-FI	M2CzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTlwMESyOUDPxE1?	NFnsfGFUSU6JRWK=
MMAC-SF	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n3b2lEPTB;OT6wPVc2OSEQvF2=	NUi2PZZIW0GQR1XS
NCI-H28	NEG1eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7ETWM2OD17LkGwOFY6KM7:TR?=	M1PP[XNCVkeHUh?=
ETK-1	NFvFW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlX5TWM2OD17LkK5PVc1KM7:TR?=	MlzLV2FPT0WU
NCI-H1993	NHrU[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSyTWM2OD17LkS0NlYyKM7:TR?=	NIrD[FZUSU6JRWK=
no-11	M2DISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHJfpVKSzVyPUmuOFcyOiEQvF2=	MXvTRW5ITVJ?
ChaGo-K-1	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HJOGlEPTB;OT61NVU5OyEQvF2=	MWLTRW5ITVJ?
NCCIT	M{i4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHOW4tKSzVyPUmuOVMyPjlizszN	MmXTV2FPT0WU
SAS	NETBSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF32coJKSzVyPUGwMlI1QCEQvF2=	MYjTRW5ITVJ?
A673	M3[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHIUmZKSzVyPUGwMlM4ODRizszN	M3HMZ3NCVkeHUh?=
NCI-H1522	M3LkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDNT3B4UUN3ME2xNE4{PzB5IN88US=>	MUTTRW5ITVJ?
NCI-H810	NHO2RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFyLkO5NFch\|ryP	MV\TRW5ITVJ?
IST-MES1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXETWM2OD1zMD60OVY1KM7:TR?=	MkfFV2FPT0WU
GR-ST	NX7JW4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXQTWM2OD1zMD61NFI1KM7:TR?=	M1vGS3NCVkeHUh?=
SUP-T1	NUPzc3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfOXVRuUUN3ME2xNE44OzF5IN88US=>	M4LBfnNCVkeHUh?=
NB5	NYDWSms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXyVFJKSzVyPUGwMlkxOjJizszN	NFKxdVFUSU6JRWK=
MZ1-PC	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PVfGlEPTB;MUCuPVU4OSEQvF2=	MlmxV2FPT0WU
SK-CO-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTFyLkm5N\|Eh\|ryP	NUXnc4NVW0GQR1XS
Capan-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqyfohXUUN3ME2xNU4{OTl6IN88US=>	NFPoUJZUSU6JRWK=
697	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknZTWM2OD1zMT62O\|U4KM7:TR?=	M{LOUHNCVkeHUh?=
REH	M13ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTFzLke0OVEh\|ryP	NFG2eoZUSU6JRWK=
GI-1	NVLOXXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFexdI5KSzVyPUGxMlg3OTVizszN	NH\Leo1USU6JRWK=
BB65-RCC	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK0RZZxUUN3ME2xNk4xQTF4IN88US=>	M2rjVHNCVkeHUh?=
NCI-H1651	NI[1NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTFZ3NKSzVyPUGyMlI1PzhizszN	M3;zcHNCVkeHUh?=
NCI-H1618	NF;2O\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HFPWlEPTB;MUKuN\|k4PiEQvF2=	MmHPV2FPT0WU
NCI-H2081	NF24[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzOfohbUUN3ME2xNk43OTRzIN88US=>	NF;XXXZUSU6JRWK=
GCIY	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLYTWM2OD1zMj63NlE{KM7:TR?=	M2\aVHNCVkeHUh?=
NY	M13wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLQR45OUUN3ME2xN{4xPjR\|IN88US=>	MUDTRW5ITVJ?
PANC-03-27	NYPtfHBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLSTWM2OD1zMz6wPFA4KM7:TR?=	MmO0V2FPT0WU
BHY	NH\HXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jJXWlEPTB;MUOuNlEzOSEQvF2=	Mn;1V2FPT0WU
SK-OV-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS4V2V1UUN3ME2xN{4{PzZ\|IN88US=>	MYHTRW5ITVJ?
5637	NEiyT\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDJTWM2OD1zMz63O\|U6KM7:TR?=	NInhbI9USU6JRWK=
LC-1F	M4LYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXPTWM2OD1zND6wN\|U3KM7:TR?=	M1zJW3NCVkeHUh?=
SNB75	NEL5TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu0TWM2OD1zND6wN\|g{KM7:TR?=	NVXOVXFEW0GQR1XS
CHP-212	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\mWmlEPTB;MUSuNFQ3PCEQvF2=	MVTTRW5ITVJ?
HT-1376	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HhWmlEPTB;MUSuNVEzPiEQvF2=	NIjXeXpUSU6JRWK=
MONO-MAC-6	NXn0[YJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TBPGlEPTB;MUSuNVUxOiEQvF2=	MknKV2FPT0WU
CA46	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF2LkG4Nlch\|ryP	M4HDO3NCVkeHUh?=
SCC-15	Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jzcGlEPTB;MUSuOVU5OyEQvF2=	M1i3NHNCVkeHUh?=
ATN-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\uTWM2OD1zND62OlI4KM7:TR?=	MlLNV2FPT0WU
NCI-H2405	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTF2LkixOVch\|ryP	NHf3b3dUSU6JRWK=
NCI-H716	M1;Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTyS5RZUUN3ME2xOE45PDl\|IN88US=>	NIjMTmhUSU6JRWK=
SW620	NUn2fJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f0fGlEPTB;MUSuPVAyPCEQvF2=	M4f2VHNCVkeHUh?=
NCI-H226	NIXPRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1uwZWlEPTB;MUSuPVA5PSEQvF2=	NHjJZmxUSU6JRWK=
SW962	NGiyVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDmSJNKSzVyPUG0Mlk1OzJizszN	NIHiPItUSU6JRWK=
KYSE-150	NELxNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\WN3Y{UUN3ME2xOE46PTVizszN	NYH5PYtEW0GQR1XS
OCUB-M	NUe0OYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7jTJdJUUN3ME2xOE46QDh\|IN88US=>	M2njOnNCVkeHUh?=
ES7	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrEWG55UUN3ME2xOU4xQTh2IN88US=>	MX\TRW5ITVJ?
SW1463	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH3TWM2OD1zNT60NlI{KM7:TR?=	NXXN[5dHW0GQR1XS
CAKI-1	NF;YenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoX0TWM2OD1zNT61N\|Q3KM7:TR?=	MkTQV2FPT0WU
MKN28	NH62ZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHOTVVKUUN3ME2xOU42PDd7IN88US=>	M1\mR3NCVkeHUh?=
SW13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDUdnpKSzVyPUG1MlYyQCEQvF2=	M4TUcHNCVkeHUh?=
A3-KAW	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\uOYJGUUN3ME2xOU46Pjl5IN88US=>	NEW1T4lUSU6JRWK=
LU-65	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF3Lkm3Olgh\|ryP	NEjpO4hUSU6JRWK=
Calu-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF4LkCzOlgh\|ryP	MY\TRW5ITVJ?
ST486	M2W5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTqXFU4UUN3ME2xOk4xPDNzIN88US=>	NWrRNFBJW0GQR1XS
BB30-HNC	NHvkWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG2T2RKSzVyPUG2MlEzPDZizszN	NHq5OpVUSU6JRWK=
EGI-1	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTF4LkS0OkDPxE1?	NUfINlJ4W0GQR1XS
SH-4	NVPHdm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn3d5JCUUN3ME2xOk41PzNzIN88US=>	M4D4eXNCVkeHUh?=
MN-60	NYPkZnBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTF5LkKyPVch\|ryP	MkPmV2FPT0WU
MPP-89	NWXRPZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[0UWlEPTB;MUeuNlQ2QSEQvF2=	MXfTRW5ITVJ?
A2780	NFLEOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7m[nBzUUN3ME2xO{41OTN7IN88US=>	Mo\CV2FPT0WU
Daoy	M2HrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7nUpBKSzVyPUG3MlQ3QTVizszN	NHTObY9USU6JRWK=
NCI-H2126	NXjIeIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\0PG5IUUN3ME2xO{41PzdzIN88US=>	M1TmdXNCVkeHUh?=
NCI-H1563	NVS0XIVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTF5LkS5NVch\|ryP	MX\TRW5ITVJ?
8-MG-BA	M17ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF5Lk[2OFgh\|ryP	MoH3V2FPT0WU
786-0	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPoUFBKSzVyPUG3Mlg{PTNizszN	M3XrXnNCVkeHUh?=
AM-38	M1LWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTkS\|FKSzVyPUG3Mlk{ODZizszN	MWPTRW5ITVJ?
COLO-824	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTF6LkS0N\|Yh\|ryP	M1zxbHNCVkeHUh?=
SK-MEL-30	NFWxdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C3OmlEPTB;MUiuOVA5OiEQvF2=	M{Pq[nNCVkeHUh?=
CESS	NVKybIFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLScnNKSzVyPUG4Mlc3ODlizszN	MlrwV2FPT0WU
BL-70	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTF6LkixOVYh\|ryP	NG\lfWhUSU6JRWK=
NCI-H2170	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHE[XhRUUN3ME2xPE46OTd7IN88US=>	M3j3eHNCVkeHUh?=
HT-3	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmSyTWM2OD1zOD65PFMh\|ryP	MVrTRW5ITVJ?
BOKU	M1\vZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPTTWM2OD1zOT6wN\|gyKM7:TR?=	Mom0V2FPT0WU
HPAF-II	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXtVZZKSzVyPUG5MlMxOTVizszN	M4fJbHNCVkeHUh?=
KGN	NHjYbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDJTlJ7UUN3ME2xPU41PzZ3IN88US=>	NW\4UHFUW0GQR1XS
MC-CAR	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fkOGlEPTB;MUmuOlMyOyEQvF2=	NXHVfoR{W0GQR1XS
BHT-101	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDU[pRKSzVyPUG5Mlc4PyEQvF2=	NYfteW46W0GQR1XS
SW1783	NHXLcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF7Lke4NFYh\|ryP	Ml3sV2FPT0WU
KP-N-YN	M4XOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7WXYtKSzVyPUKwMlAzPjJizszN	NUTkV\|M{W0GQR1XS
LU-165	NX\Nd\|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe2TnhtUUN3ME2yNE42PTdzIN88US=>	NY\WeVNCW0GQR1XS
GOTO	NGPvXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7WXplmUUN3ME2yNE43PDVzIN88US=>	NX\xNZB3W0GQR1XS
EFM-19	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFy4WolKSzVyPUKxMlA4OTZizszN	MmnLV2FPT0WU
CTV-1	NWjKTVI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELMXWJKSzVyPUKxMlExPTRizszN	M4TQWHNCVkeHUh?=
HEL	M2HCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTjZ3JoUUN3ME2yNU41OjF4IN88US=>	NHvBfIxUSU6JRWK=
SNU-C2B	NUS2Ull5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJzLkSyOkDPxE1?	M1jWenNCVkeHUh?=
ECC4	NEHzfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojPTWM2OD1{MT63NFch\|ryP	NWixcWpEW0GQR1XS
NEC8	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILOV4dKSzVyPUKxMlg{PjhizszN	M{\BZ3NCVkeHUh?=
KMOE-2	NIjROWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{SzOWlEPTB;MkGuPFkzOSEQvF2=	NV;0ZoZ2W0GQR1XS
NCI-H524	M3LZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGi0PGxKSzVyPUKyMlA5ODhizszN	MkflV2FPT0WU
WSU-NHL	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\NTWM2OD1{Mj6xOVc4KM7:TR?=	NHXKWW9USU6JRWK=
SF126	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJ{LkK0Olkh\|ryP	MkjtV2FPT0WU
HOP-92	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fRWmlEPTB;MkKuN\|E3PyEQvF2=	NF\V[29USU6JRWK=
CTB-1	M2\0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJ{LkS2O\|ch\|ryP	NFfieIxUSU6JRWK=
KYSE-270	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rRSWlEPTB;MkKuPVM2PyEQvF2=	MUHTRW5ITVJ?
SK-MEL-24	NETzVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7nN45KSzVyPUKzMlE5PyEQvF2=	M3;OVHNCVkeHUh?=
Calu-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTJ\|LkKxNlgh\|ryP	MYLTRW5ITVJ?
GAMG	NVS5VpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfrcIptUUN3ME2yN{4zOzZ5IN88US=>	M3nWW3NCVkeHUh?=
SW1573	NV\pOm55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L1UWlEPTB;MkOuO\|QyPSEQvF2=	MU\TRW5ITVJ?
MHH-NB-11	NVy0RZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ2LkCxPVQh\|ryP	MUnTRW5ITVJ?
TK10	NELWV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUSzPIdzUUN3ME2yOE42ODF\|IN88US=>	NHLiPVZUSU6JRWK=
LB373-MEL-D	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13PZ2lEPTB;MkSuOlA3PCEQvF2=	NFPHd3JUSU6JRWK=
KALS-1	NW\5[VF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTJ2LkezNlch\|ryP	MVjTRW5ITVJ?
HUTU-80	NETGPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTJ3LkiwN\|Ih\|ryP	NF7X[FhUSU6JRWK=
HuP-T3	NFPEUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnt[3hHUUN3ME2yOk4yPjd2IN88US=>	MY\TRW5ITVJ?
OE19	NWDodIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ4LkKxOVMh\|ryP	MU\TRW5ITVJ?
J82	NFfmSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXHTWM2OD1{Nj6yOFcyKM7:TR?=	NXLBdlQ3W0GQR1XS
DU-4475	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH3OGFKSzVyPUK2MlM5OTlizszN	NH7PRoFUSU6JRWK=
DMS-53	NX\HT3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJ4LkWxN\|gh\|ryP	MULTRW5ITVJ?
COLO-741	NIDXT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Cz[GlEPTB;Mk[uPFM1PCEQvF2=	MU\TRW5ITVJ?
SW48	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJ4Lki4NkDPxE1?	NX\lbJJpW0GQR1XS
IGR-1	M4Pie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7XSodKSzVyPUK2Mlk{OzRizszN	MUPTRW5ITVJ?
639-V	NFzSV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV73eVQ3UUN3ME2yO{4xOjR3IN88US=>	Mmf0V2FPT0WU
LK-2	NXjjOI5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LhXGlEPTB;MkeuOFE1OSEQvF2=	M1K5c3NCVkeHUh?=
NCI-H2347	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlroTWM2OD1{Nz65Olk6KM7:TR?=	MWXTRW5ITVJ?
NCI-H2228	M4\Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXS1bmNJUUN3ME2yPE4xQTB3IN88US=>	M2HFd3NCVkeHUh?=
LS-123	M4C2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\kSZNKSzVyPUK4MlEzPjJizszN	MmX1V2FPT0WU
U031	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m2ZmlEPTB;MkiuNlUzKM7:TR?=	MorvV2FPT0WU
NCI-H1792	NFvXdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLLTWM2OD1{OD60O\|IyKM7:TR?=	NVjRbY05W0GQR1XS
NCI-H2087	NVTBRXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DpNWlEPTB;MkiuO\|U2OiEQvF2=	MYnTRW5ITVJ?
NCI-H2342	NXeweIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfBbmczUUN3ME2yPU42OjB6IN88US=>	MWrTRW5ITVJ?
SW626	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPHTWM2OD1{OT63OVYh\|ryP	MkLYV2FPT0WU
LB2518-MEL	M2PwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ7LkixOUDPxE1?	M{LNV3NCVkeHUh?=
RXF393	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonBTWM2OD1\|MD6wPVUzKM7:TR?=	MWfTRW5ITVJ?
LC4-1	NFvBfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XTUGlEPTB;M{CuN\|A6OiEQvF2=	MnHmV2FPT0WU
NCI-H1694	M1vsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXTelFGUUN3ME2zNE43PjJ2IN88US=>	Mn;kV2FPT0WU
K5	NHLaTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2SzTWlEPTB;M{CuPVcxOiEQvF2=	M1PJU3NCVkeHUh?=
HDLM-2	NGDEcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHSbZptUUN3ME2zNE46PzJ3IN88US=>	M4rMW3NCVkeHUh?=
BCPAP	NUC5e3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrDTWM2OD1\|MT64N\|c6KM7:TR?=	M13ONHNCVkeHUh?=
BC-3	NGXiRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3vRnZKSzVyPUOyMlE1ODNizszN	NUDUR\|BJW0GQR1XS
LB996-RCC	M3\jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3SSZpKSzVyPUOyMlI{PThizszN	Mor0V2FPT0WU
NCI-H2009	NUjYT4dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXFTWM2OD1\|Mj60PVgyKM7:TR?=	MVXTRW5ITVJ?
HTC-C3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXWO2J7UUN3ME2zN{44PTF7IN88US=>	MV3TRW5ITVJ?
LAMA-84	M2nT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vO[mlEPTB;M{SuOFQxPyEQvF2=	MXvTRW5ITVJ?
CCRF-CEM	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEftOHlKSzVyPUO0MlU4OTVizszN	MoXNV2FPT0WU
AN3-CA	NXjuNYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vIRWlEPTB;M{WuNFU3QCEQvF2=	MW\TRW5ITVJ?
NCI-H1734	NUDRdJRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPuZZFLUUN3ME2zOU4zPTZzIN88US=>	MlXmV2FPT0WU
Ca-Ski	NFTCeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;STmtKSzVyPUO1MlQyODFizszN	MYrTRW5ITVJ?
U-266	NHfvVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r5W2lEPTB;M{WuOlEyPCEQvF2=	MYXTRW5ITVJ?
SBC-5	NXjYRmQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXrTWM2OD1\|NT63O\|gyKM7:TR?=	NYHPeYR5W0GQR1XS
GT3TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXhUoxKSzVyPUO3MlEyPSEQvF2=	MoLMV2FPT0WU
MDA-MB-175-VII	M2DSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X3N2lEPTB;M{euNlI1QCEQvF2=	MVnTRW5ITVJ?
PFSK-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWi1TnY5UUN3ME2zO{4zPDN3IN88US=>	M2TEVXNCVkeHUh?=
IMR-5	NW\1[FdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHmPFR1UUN3ME2zO{4zPDh5IN88US=>	MWHTRW5ITVJ?
Daudi	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPhUlFKSzVyPUO3MlM2QTdizszN	M4r3TXNCVkeHUh?=
A498	M2TUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHvTWM2OD1\|Nz63NlE5KM7:TR?=	MkjwV2FPT0WU
SCC-4	NFn2eFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4POUmlEPTB;M{euO\|g1OyEQvF2=	NHvheHRUSU6JRWK=
COLO-680N	M2rvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\Ob2lEPTB;M{iuNlg5PSEQvF2=	MnvxV2FPT0WU
SK-MES-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTN6LkOyNVUh\|ryP	MljaV2FPT0WU
SR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnxTWM2OD1\|OD61OFk2KM7:TR?=	M1n4SnNCVkeHUh?=
LNCaP-Clone-FGC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTN6LkW2N\|ch\|ryP	Mn\RV2FPT0WU
SK-HEP-1	NFjVZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTN6Lke4NlIh\|ryP	M1fpNXNCVkeHUh?=
BPH-1	NXX4OphiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHpT2h[UUN3ME2zPE45OzJ7IN88US=>	M3PPfXNCVkeHUh?=
NCI-H1755	MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jJc2lEPTB;M{muOVgyPyEQvF2=	NGTVdGRUSU6JRWK=
LXF-289	NIjLfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTN7LkiwPFQh\|ryP	M{DwVHNCVkeHUh?=
SW1088	NU[yOotqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH2TWM2OD12MD6yNVA4KM7:TR?=	Mmf1V2FPT0WU
MOLT-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTRyLkK5NFEh\|ryP	MX7TRW5ITVJ?
AsPC-1	NHXiV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly3TWM2OD12MD60OVg{KM7:TR?=	NESzWodUSU6JRWK=
HOP-62	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PqNWlEPTB;NECuOlU3QCEQvF2=	MlnqV2FPT0WU
A172	M1XH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXEe3FKSzVyPUSwMlg2OTFizszN	Mo[4V2FPT0WU
SN12C	NIe4O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PoW2lEPTB;NECuPVM5PSEQvF2=	Mk\vV2FPT0WU
MDA-MB-231	NXr2c3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHEcWhOUUN3ME20NE46QDl6IN88US=>	NHSyUFdUSU6JRWK=
RPMI-2650	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfoNIlKSzVyPUSxMlE2QTNizszN	MU\TRW5ITVJ?
KYSE-140	M2S0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTRzLkixNlMh\|ryP	M4nwSnNCVkeHUh?=
KINGS-1	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Ow[WlEPTB;NEKuOFY6PyEQvF2=	MoHEV2FPT0WU
HSC-3	NG\Z[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CwOmlEPTB;NEKuOlY3OSEQvF2=	NUnxS29uW0GQR1XS
PC-14	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETlUGtKSzVyPUSzMlE5QDJizszN	MWrTRW5ITVJ?
COR-L105	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3FOWFqUUN3ME20N{43PTB{IN88US=>	NYnLc2ZlW0GQR1XS
BE-13	NH3tOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37VSWlEPTB;NESuNlM4OSEQvF2=	MlX5V2FPT0WU
NCI-H661	M4PGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\WflVSUUN3ME20OE4zQTV6IN88US=>	NHzwS4tUSU6JRWK=
IST-MEL1	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXtTVZKSzVyPUS0MlM2QTlizszN	NYCzNm9NW0GQR1XS
HCC1806	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:yV2lEPTB;NESuOVg4OyEQvF2=	NILJOG9USU6JRWK=
COLO-800	M4jm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW2e2FxUUN3ME20OE45PDV\|IN88US=>	NULqe2dCW0GQR1XS
IST-SL2	NUjGO2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq4UpdTUUN3ME20OU4yOjR5IN88US=>	MUHTRW5ITVJ?
8305C	NILGTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTR3LkOwPUDPxE1?	MmfEV2FPT0WU
UACC-62	NH\NW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MluzTWM2OD12Nj6yPFc2KM7:TR?=	NF\NOnBUSU6JRWK=
COR-L23	NV;Wb3FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTR5LkG5PUDPxE1?	NUm4WXRFW0GQR1XS
EFE-184	M{XHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj5TWM2OD12Nz6zPFgh\|ryP	NEjjPVhUSU6JRWK=
DMS-114	M3nuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrHcGU2UUN3ME20O{41OTR7IN88US=>	M4HhfnNCVkeHUh?=
KYSE-520	M3X4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV65dG5iUUN3ME20PE42OzF3IN88US=>	NFPqOGtUSU6JRWK=
SNG-M	NHfzc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;pfWlEPTB;NEmuOFM1KM7:TR?=	MmLJV2FPT0WU
A2058	NH64fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTR7LkS4PFUh\|ryP	NY\FVnoxW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	+ Expand Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Formulation: 25 mM tartaric acid Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 59 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 59 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)